For many patients and families facing complex blood cancers, searching for CAR-T therapy in Barcelona usually comes at a very important moment: after previous treatments, different medical opinions, and the need to understand whether an advanced therapy may offer a new option.
CAR-T cell therapy is one of the most innovative areas in modern cancer care. It is especially relevant for selected patients with certain hematological cancers, such as leukemia, lymphoma or multiple myeloma. This article explains what CAR-T therapy is, when it may be considered, why it requires highly specialised hospitals, and what international patients should know before requesting an evaluation in Barcelona.
What is CAR-T therapy?
CAR-T therapy, also known as Teràpia amb cèl·lules CAR-T, is a type of personalised immunotherapy. Unlike conventional treatments that use standard drugs, CAR-T therapy works by using the patient’s own immune cells.
The term CAR-T stands for Chimeric Antigen Receptor T-cell therapy. In simple terms, doctors collect T cells from the patient’s blood, modify them in a specialised laboratory so they can recognise specific cancer cells, and then infuse them back into the patient.
Once inside the body, these modified cells are designed to identify and attack cancer cells with certain markers. This makes CAR-T therapy a highly personalised treatment, because it is created using the patient’s own immune system. However, CAR-T therapy is not suitable for every patient or every type of cancer. Today, it is mainly used in selected cases of complex blood cancers, especially when the disease has returned after previous treatments or has not responded as expected.
Which cancers can CAR-T therapy treat?
The exact indication depends on the patient’s diagnosis, age, previous treatments, current condition and the specific CAR-T product available. In general, CAR-T treatment is most commonly associated with certain hematological cancers.
| Disease area | How CAR-T therapy may be relevant | Important note for international patients |
|---|---|---|
| Acute lymphoblastic leukemia | Acute lymphoblastic leukemia, often called ALL, is one of the diseases where CAR-T therapy has become especially relevant, including in pediatric care. | It may be considered in selected cases when the disease has relapsed or has not responded adequately to previous treatment. |
| Certain types of lymphoma | Some forms of lymphoma may also be treated with CAR-T therapy. | Suitability depends on the lymphoma subtype, previous treatments and the patient’s clinical situation. |
| Multiple myeloma | CAR-T therapy is also being used or studied in selected cases of multiple myeloma, especially in advanced or relapsed disease. | Eligibility must always be assessed by a specialised hematology team. |
| Other diseases under research | Research into CAR-T therapy and other advanced cellular therapies is moving quickly. | Not every experimental indication is clinically available, and not every patient is eligible for treatment. |
Why CAR-T therapy requires highly specialised hospitals
CAR-T therapy is not only advanced because of the science behind it. It is also complex because the full treatment process requires coordination between many medical teams.
A patient may need evaluation by hematologists, oncologists, immunotherapy specialists, intensive care teams, laboratory experts, nurses trained in advanced therapies, infectious disease specialists and international patient coordinators. This is why CAR-T therapy in Spain is usually provided in highly specialised hospitals with experience in complex cancer care.
The process may include:
- Reviewing the patient’s diagnosis and previous treatments.
- Confirming whether the disease may be suitable for CAR-T therapy.
- Assessing the patient’s general health and possible risks.
- Collecting immune cells from the patient.
- Preparing or manufacturing the CAR-T product.
- Administering preparatory treatment before infusion, when needed.
- Infusing the modified cells.
- Monitoring the patient closely after treatment.
This last stage is especially important. CAR-T therapy can cause side effects that require immediate medical attention. For this reason, patients need care in centres with trained teams, clear clinical protocols and the right hospital infrastructure.
CAR-T therapy in Barcelona: why the city matters
Barcelona has become one of Europe’s most recognised medical cities for advanced care. The city combines university hospitals, private medical centres, research institutions, biomedical innovation and international patient services.
For patients searching for CAR-T therapy in Barcelona, this ecosystem is important. CAR-T is not a simple treatment that depends on one specialist only. It requires diagnostic precision, hospital coordination, advanced laboratories, intensive monitoring and long-term follow-up.
Barcelona is also a well-connected European city, with international flights, accommodation options, multilingual services and hospitals used to caring for patients from abroad. This can make the treatment journey easier for international patients and families who need medical care in another country.
Adult and pediatric CAR-T therapy pathways
One important aspect of CAR-T therapy is that adult and pediatric pathways are not the same.
Children with leukemia require a pediatric hospital with specific experience in childhood cancer, pediatric intensive care, family support and long-term follow-up. Within the Barcelona International Hospitals network, Hospital Infantil SJD Barcelona is especially relevant for pediatric patients and families exploring advanced therapies such as CAR-T in complex childhood blood cancers.
Adult patients usually require evaluation by adult hematology and oncology specialists. In Barcelona, barnaclínic+ – Grupo Hospital Clínic is especially relevant for adult patients because of its connection with Hospital Clínic Barcelona and its experience in advanced hematology, oncology and CAR-T therapies.
For international patients, this distinction matters. The best hospital is not simply the one with the most advanced technology, but the one with the right expertise for the patient’s age, diagnosis and clinical situation.
Why multidisciplinary care is essential
CAR-T therapy is often described as a treatment, but for the patient it is a complete medical journey. Before the infusion takes place, the case must be carefully reviewed by specialists.
A multidisciplinary team can help answer key questions:
Is CAR-T therapy appropriate for this case?
Not every patient with leukemia, lymphoma or multiple myeloma is a candidate. Doctors need to review the exact diagnosis, disease stage, previous treatments, test results and overall health.
Is the patient stable enough to travel?
For international patients, this is critical. Travelling for advanced cancer treatment requires careful planning. The hospital must assess whether the patient can safely travel, how urgent the case is and what medical support may be needed.
What happens if CAR-T therapy is not the best option?
Sometimes, the specialist may recommend another treatment, a clinical trial, transplant evaluation, systemic therapy, radiotherapy or supportive care. A good medical evaluation should clarify the safest and most realistic options, not simply promise access to a specific therapy.
How will the patient be monitored after treatment?
CAR-T therapy does not end with the infusion. Patients need follow-up to monitor response, side effects, infections, immune recovery and possible relapse. For international patients, coordination between the Barcelona hospital and the medical team in the patient’s home country may also be necessary.
BIH hospitals relevant to CAR-T therapy and complex cancer care
Barcelona International Hospitals brings together leading hospitals in Barcelona with different areas of excellence. For CAR-T therapy and advanced hematological cancer care, two centres are especially relevant:
barnaclínic+ – Grupo Hospital Clínic
barnaclínic+ – Grupo Hospital Clínic is particularly relevant for adult patients who need advanced hematology, oncology, immunotherapy, clinical research and evaluation for complex blood cancers.
Hospital Sant Joan de Déu Barcelona
Hospital Infantil SJD Barcelona is especially relevant for pediatric patients with complex diseases and CAR-T treatment, including childhood leukemia and other advanced pediatric oncology cases.
Depending on each patient’s needs, the wider BIH network may also help coordinate complementary diagnosis, surgery, rehabilitation or follow-up through partner hospitals such as Centro Médico Teknon, Hospital Quirónsalud Barcelona, Hospital Universitari Dexeus, Fundació Puigvert i Institut Guttmann.
Not all hospitals in the network provide CAR-T therapy directly. The value of BIH lies in helping international patients identify the most appropriate hospital pathway according to their diagnosis, age and medical needs.
What international patients should prepare before requesting evaluation
If you are considering CAR-T therapy in Barcelona, the first step is usually not to travel immediately. The first step is to prepare a complete medical file so specialists can assess the case properly.
The following checklist can help international patients organise the main documents usually needed before requesting a medical evaluation:
| Document or information | Why it matters |
|---|---|
| Updated diagnosis report | Helps specialists understand the current diagnosis and stage of the disease. |
| Pathology and immunohistochemistry reports | Provides essential information about the type of cancer and its biological characteristics. |
| Genetic or molecular test results | May help specialists assess whether advanced or personalised treatment options are relevant. |
| Imaging studies such as PET-CT, CT, MRI or ultrasound | Allows the medical team to review the extent and evolution of the disease. |
| Blood test results | Shows the patient’s general health status and may help identify risks before treatment. |
| Bone marrow reports, when relevant | Important in many hematological cancers, especially leukemia, lymphoma or multiple myeloma. |
| Details of previous treatments | Helps doctors understand what therapies have already been used and how the disease responded. |
| Dates of chemotherapy, immunotherapy, transplant or radiotherapy | Provides a clear timeline of the patient’s treatment history. |
| Current medications | Helps assess possible interactions, risks or supportive care needs. |
| Recent discharge reports | Gives specialists updated information about hospital admissions, complications or recent procedures. |
| Information about infections or complications | Important because CAR-T therapy requires careful evaluation of the patient’s overall clinical condition. |
| Short clinical summary in English, if possible | Can make the first review faster and easier for international medical teams. |
In complex cancer care, missing documents can delay the medical review.
Second medical opinion for CAR-T therapy in Barcelona
Many international patients do not initially know whether they need treatment abroad or simply a second medical opinion. In CAR-T therapy, a segona opinió mèdica can be especially valuable because it can help clarify whether the patient may be eligible, whether another treatment should be considered first, or whether the case should be reviewed by a specialised medical team.
A second opinion may be useful when:
- The cancer has returned after previous treatment.
- Standard therapies have not achieved the expected response.
- The patient has received different recommendations from different doctors.
- The family wants to understand whether CAR-T therapy is realistic.
- A doctor in the home country has suggested looking for advanced treatment abroad.
- The patient wants to compare treatment options in Spain or Europe.
A good second opinion should explain possibilities and limitations clearly. It should not promise access to CAR-T therapy before specialists have reviewed the case.
FAQs about CAR-T therapy in Barcelona
Is CAR-T therapy available in Barcelona?
What is CAR-T therapy used for?
Can children receive CAR-T therapy in Barcelona?
Is CAR-T therapy the same as chemotherapy?
Can international patients request a second opinion for CAR-T therapy?
What documents are needed before requesting evaluation?
Conclusion: CAR-T therapy requires the right hospital ecosystem
CAR-T therapy represents one of the most important advances in personalised cancer treatment, particularly for selected patients with complex blood cancers. However, it is not a simple or universal treatment. It requires advanced laboratories, experienced specialists, multidisciplinary teams, careful monitoring and clear communication with patients and families.
For international patients, CAR-T therapy in Barcelona offers access to a city with strong experience in high-complexity medicine, advanced research, pediatric and adult oncology, and international patient care.
Within Barcelona International Hospitals, centres such as barnaclínic+ – Grupo Hospital Clínic i Hospital Infantil SJD Barcelona are especially relevant for patients exploring CAR-T therapy, while the broader BIH network provides a wider ecosystem of specialised medical expertise across diagnosis, oncology, surgery, rehabilitation and complex care.
If you are considering CAR-T therapy or need a second medical opinion for a complex blood cancer, you can contact Barcelona International Hospitals to help identify the most appropriate specialist pathway for your case:
Contacta amb els Hospitals Internacionals de Barcelona
This article is for informational purposes only and should not replace professional medical advice. Always consult a qualified specialist regarding your individual case.
